TFAP2C-DDR1 axis regulates resistance to CDK4/6 inhibitor in breast cancer
Cancer Letters · 2025
DOI: 10.1016/j.canlet.2024.217356 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Muhammad Jameel Mughal und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Medicine, GWU Cancer Center, George Washington University School of Medicine and Health Sciences, Washington…. Hauptthemen laut MEDLINE: Breast Neoplasms, Drug Resistance, Neoplasm, Cyclin-Dependent Kinase 4, Piperazines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health, National Center for Advancing Translational Sciences.
Abstract (Originalsprache)
Breast cancer is the predominant malignancy with the majority of cases are characterized as HR+/HER2-subtype. Although cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have shown remarkable efficacy in treating this subtype when combined with endocrine therapy, the development of resistance to these inhibitors remains a significant clinical obstacle. Hence, there is an urgent need to explore innovative therapies and decipher the underlying mechanisms of resistance to CDK4/6i. In this study, we employed quantitative high-throughput combination screening (qHTCS) and genomics/proteomics approaches to uncover the molecular mechanisms driving resistance to CDK4/6i (palbociclib) in breast cancer. The comprehensive analyses revealed DDR1 as a potential factor implicated in mediating resistance to CDK4/6i. Specifically, DDR1 inhibition in combination with palbociclib exhibited remarkable synergistic effects, reducing cell survival signaling and promoting apoptosis in resistant cells. In-vivo xenograft model further validated the synergistic effects, showing a significant reduction in the resistant tumor growth. Exploration into DDR1 activation uncovered TFAP2C as a key transcription factor regulating DDR1 expression in palbociclib resistant cells and inhibition of TFAP2C re-sensitized resistant cells to palbociclib. Gene set enrichment analysis (GSEA) in the NeoPalAna trial demonstrated a significant enrichment of the TFAP2C-DDR1 gene set from patitens after palbociclib treatment, suggesting the possible activation of the TFAP2C-DDR1 axis following palbociclib exposure. Overall, this study provides crucial insights into the novel molecular landscape of palbociclib resistance in breast cancer, suggesting TFAP2C-DDR1 axis inhibition as a promising strategy to overcome resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Medicine, GWU Cancer Center, George Washington University School of Medicine and Health Sciences, Washington, DC, 20037, USA.
- Early Translation Branch, Division of Preclinical Innovation, National Center for Translational Sciences (NCATS), National Institutes of Health (NIH), Rockville, MD, 20850, USA.
- Department of Biochemistry and Molecular Medicine, GWU Cancer Center, George Washington University School of Medicine and Health Sciences, Washington, DC, 20037, USA. Electronic address: wz6812@gwu.edu.
Förderung
- NCI NIH HHS
- National Institutes of Health
- National Center for Advancing Translational Sciences
- George Washington University
Zitieren
APA
Mughal, M. J., Zhang, Y., Li, Z., Zhou, S., Peng, C., Zhang, Y. Q., Seto, E., Shen, M., Hall, M. D., & Zhu, W. (2025). TFAP2C-DDR1 axis regulates resistance to CDK4/6 inhibitor in breast cancer. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.217356
Vancouver
Mughal MJ, Zhang Y, Li Z, Zhou S, Peng C, Zhang YQ, et al. TFAP2C-DDR1 axis regulates resistance to CDK4/6 inhibitor in breast cancer. Cancer Letters. 2025. doi:10.1016/j.canlet.2024.217356
BibTeX
@article{Mughal2025,
author = {Mughal, Muhammad Jameel and Zhang, Yi and Li, Zhuqing and Zhou, Shuyan and Peng, Changmin and Zhang, Ya-Qin and Seto, Edward and Shen, Min and Hall, Matthew D and Zhu, Wenge},
title = {TFAP2C-DDR1 axis regulates resistance to CDK4/6 inhibitor in breast cancer},
journal = {Cancer Letters},
year = {2025},
doi = {10.1016/j.canlet.2024.217356}
}
EUVIMED